Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 3
1(25.0%)
Phase 2
1(25.0%)
4Total
Phase 1(2)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00003225Phase 1Completed

Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Role: collaborator

NCT00177281Phase 1Completed

Safety Study of S-CKD602 in Patients With Advanced Malignancies

Role: collaborator

NCT00003827Phase 2Unknown

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Role: lead

NCT00653952Phase 3Terminated

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Role: collaborator

All 4 trials loaded